Psychotropic Medication Use among Insured Children with Autism Spectrum Disorder / Jeanne M. MADDEN in Journal of Autism and Developmental Disorders, 47-1 (January 2017)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 47-1 (January 2017) . - p.144-154 Titre : Psychotropic Medication Use among Insured Children with Autism Spectrum Disorder Type de document : Texte imprimé et/ou numérique Auteurs : Jeanne M. MADDEN, Auteur ; Matthew D. LAKOMA, Auteur ; Frances L. LYNCH, Auteur ; Donna RUSINAK, Auteur ; Ashli A. OWEN-SMITH, Auteur ; Karen J. COLEMAN, Auteur ; Virginia P. QUINN, Auteur ; Vincent M. YAU, Auteur ; Yinge X. QIAN, Auteur ; Lisa A. CROEN, Auteur Article en page(s) : p.144-154 Langues : Anglais (eng) Mots-clés : Autism spectrum disorder  Medications  Antipsychotics  Comorbidities  Epidemiological studies Index. décimale : PER Périodiques Résumé : This study examined psychotropic medication use among 7901 children aged 1–17 with autism spectrum disorder (ASD) in five health systems, comparing to matched cohorts with no ASD. Nearly half (48.5?%) of children with ASD received psychotropics in the year observed; the most common classes were stimulants, alpha-agonists, or atomoxetine (30.2?%), antipsychotics (20.5?%), and antidepressants (17.8?%). Psychotropic treatment was far more prevalent among children with ASD, as compared to children with no ASD (7.7?% overall), even within strata defined by the presence or absence of other psychiatric diagnoses. The widespread use of psychotropics we observed, particularly given weak evidence supporting the effectiveness of these medications for most children with ASD, highlights challenges in ASD treatment and the need for greater investment in its evaluation. En ligne : http://dx.doi.org/10.1007/s10803-016-2946-7 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=298 [article] Psychotropic Medication Use among Insured Children with Autism Spectrum Disorder [Texte imprimé et/ou numérique] / Jeanne M. MADDEN, Auteur ; Matthew D. LAKOMA, Auteur ; Frances L. LYNCH, Auteur ; Donna RUSINAK, Auteur ; Ashli A. OWEN-SMITH, Auteur ; Karen J. COLEMAN, Auteur ; Virginia P. QUINN, Auteur ; Vincent M. YAU, Auteur ; Yinge X. QIAN, Auteur ; Lisa A. CROEN, Auteur . - p.144-154. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 47-1 (January 2017) . - p.144-154 Mots-clés : Autism spectrum disorder  Medications  Antipsychotics  Comorbidities  Epidemiological studies Index. décimale : PER Périodiques Résumé : This study examined psychotropic medication use among 7901 children aged 1–17 with autism spectrum disorder (ASD) in five health systems, comparing to matched cohorts with no ASD. Nearly half (48.5?%) of children with ASD received psychotropics in the year observed; the most common classes were stimulants, alpha-agonists, or atomoxetine (30.2?%), antipsychotics (20.5?%), and antidepressants (17.8?%). Psychotropic treatment was far more prevalent among children with ASD, as compared to children with no ASD (7.7?% overall), even within strata defined by the presence or absence of other psychiatric diagnoses. The widespread use of psychotropics we observed, particularly given weak evidence supporting the effectiveness of these medications for most children with ASD, highlights challenges in ASD treatment and the need for greater investment in its evaluation. En ligne : http://dx.doi.org/10.1007/s10803-016-2946-7 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=298

---

1 (1 - 1 / 1)